ANNEX I

In Annex III to Regulation (EC) No 1223/2009, the following entry is added:

Reference number

Substance identification

Restrictions

Wording of conditions of use and warnings

Chemical name/INN

Name of Common Ingredients Glossary

CAS number

EC number

Product type, body parts

Maximum concentration in ready for use preparation

Other

a

b

c

d

e

f

g

h

i

‘310

1-(4-Chlorophenoxy)- 1-(imidazol-1-yl)-3,3- dimethylbutan-2-one3

Climbazole

38083-17-9

253-775-4

Rinse-off anti-dandruff shampoo4

2,0 %4

For purposes other than inhibiting the development of micro-organisms in the product. This purpose has to be apparent from the presentation of the product.4

For use as a preservative, see Annex V, entry 32.

From 27 November 2019 cosmetic products containing 1-(4-Chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutan-2-one and not complying with those restrictions shall not be placed on the Union market.

From 27 February 2020 cosmetic products containing 1-(4-Chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutan-2-one and not complying with those restrictions shall not be made available on the Union market.’

ANNEX II

Reference number

Substance Identification

Conditions

Wording of conditions of use and warnings

Chemical name/INN

Name of Common Ingredients Glossary

CAS number

EC number

Product type, Body parts

Maximum concentration in ready for use preparation

Other

a

b

c

d

e

f

g

h

i

‘32

1-(4-Chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutan-2-one5

Climbazole

38083-17-9

253-775-4

  1. (a)

    Hair lotions6

  2. (b)

    Face creams6

  3. (c)

    Foot care products6

  4. (d)

    Rinse-off shampoo6

  1. (a)

    0,2 %6

  2. (b)

    0,2 %6

  3. (c)

    0,2 %6

  4. (d)

    0,5 %6

For use other than as a preservative, see Annex III, entry 310.

From 27 November 2019 cosmetic products containing 1-(4-Chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutan-2-one and not complying with those conditions shall not be placed on the Union market.

From 27 February 2020 cosmetic products containing 1-(4-Chlorophenoxy)-1-(imidazol-1-yl)-3,3-dimethylbutan-2-one and not complying with those conditions shall not be made available on the Union market.’